OrthoPediatrics Corp. (NASDAQ:KIDS – Get Free Report) major shareholder Jennifer Pritzker sold 22,500 shares of the company’s stock in a transaction on Wednesday, September 2nd. The shares were sold at an average price of $23.35, for a total value of $525,375.00. Following the sale, the insider owned 6,504,133 shares of the company’s stock, valued at approximately $151,871,505.55. The trade was a 0.34% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink. Large shareholders that own 10% or more of a company’s shares are required to disclose their transactions with the SEC.
OrthoPediatrics Price Performance
KIDS traded down $0.18 on Friday, hitting $22.41. 129,506 shares of the stock were exchanged, compared to its average volume of 173,525. OrthoPediatrics Corp. has a 12 month low of $14.42 and a 12 month high of $26.74. The firm has a market capitalization of $585.13 million, a price-to-earnings ratio of -13.34 and a beta of 0.99. The company has a debt-to-equity ratio of 0.28, a current ratio of 4.78 and a quick ratio of 2.17. The business has a 50-day moving average of $21.74 and a two-hundred day moving average of $18.84.
OrthoPediatrics (NASDAQ:KIDS – Get Free Report) last issued its earnings results on Tuesday, August 4th. The company reported ($0.26) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.30) by $0.04. The firm had revenue of $70.51 million for the quarter, compared to the consensus estimate of $68.21 million. OrthoPediatrics had a negative return on equity of 8.10% and a negative net margin of 15.72%. Sell-side analysts forecast that OrthoPediatrics Corp. will post -1.14 EPS for the current fiscal year.
Institutional Trading of OrthoPediatrics
Wall Street Analyst Weigh In
Several analysts recently weighed in on KIDS shares. Weiss Ratings raised shares of OrthoPediatrics from a “sell (e+)” rating to a “sell (d-)” rating in a research note on Wednesday, August 5th. Needham & Company LLC lifted their price target on shares of OrthoPediatrics from $30.00 to $35.00 and gave the company a “buy” rating in a research note on Wednesday, August 5th. BTIG Research increased their target price on OrthoPediatrics from $24.00 to $29.00 and gave the stock a “buy” rating in a report on Thursday, August 20th. Truist Financial set a $22.00 price objective on OrthoPediatrics in a report on Wednesday, August 5th. Finally, Piper Sandler reaffirmed an “overweight” rating and issued a $25.00 target price (up from $22.00) on shares of OrthoPediatrics in a report on Wednesday, August 5th. Nine equities research analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has assigned a Sell rating to the stock. According to data from MarketBeat, the company currently has a consensus rating of “Moderate Buy” and an average target price of $26.44.
Get Our Latest Stock Report on KIDS
About OrthoPediatrics
OrthoPediatrics Corp., founded in 2007 and headquartered in Warsaw, Indiana, is a medical device company dedicated exclusively to providing orthopedic solutions for children. The company focuses on developing, manufacturing and marketing a broad portfolio of implants and instruments designed to address a wide range of pediatric conditions, including trauma, deformity correction, spine disorders and sports injuries.
The company’s product lines include locking plates and screws for upper and lower extremity reconstruction, intramedullary nails for femur and tibia stabilization, and specialized systems such as the MAGEC Magnetic Growth Rod for treatment of early-onset scoliosis.
See Also
- Five stocks we like better than OrthoPediatrics
- Revolution Medicines Got Its Breakthrough—What Moves It Next?
- Retail Earnings Just Exposed a Bigger Divide in the U.S. Consumer Economy
- FB Financial’s Southern Expansion and Buybacks Drive Analyst Optimism
- AST SpaceMobile Stock Soared 12%—This Was the Catalyst
Receive News & Ratings for OrthoPediatrics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for OrthoPediatrics and related companies with MarketBeat.com's FREE daily email newsletter.
